- Q1 2024 Zymeworks Inc Earnings Call TranscriptMay 02, 2024$9 (+2.74%)Earnings
- Q4 2023 Zymeworks Inc Earnings Call TranscriptMar 06, 2024$12.23 (+2.09%)Earnings
- Zymeworks Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 22, 2024
- Zymeworks Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Zymeworks Inc Earnings Call TranscriptNov 07, 2023$7.37 (+1.24%)Earnings
- Zymeworks Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Zymeworks Inc at Citi BioPharma Conference TranscriptSep 06, 2023
- Q2 2023 Zymeworks Inc Earnings Call TranscriptAug 10, 2023$7.76 (+0.78%)Earnings
- Zymeworks Inc at Bank of America Global Healthcare Conference TranscriptMay 11, 2023
- Q1 2023 Zymeworks Inc Earnings Call TranscriptMay 08, 2023$8.76 (+1.39%)Earnings
- Zymeworks Inc Investor Call TranscriptApr 18, 2023
- Zymeworks Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2023
- Q4 2022 Zymeworks Inc Earnings Call TranscriptMar 07, 2023$7.96 (+0.13%)Earnings
- Zymeworks Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Zymeworks Inc HERIZON-BTC-01 Top-Line Results Call TranscriptDec 19, 2022
Zymeworks Inc at JPMorgan Healthcare Conference Transcript
&-
Good morning, everyone. Thanks for joining us for a session at the 42nd JPMorgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here. I'm joined by my associates, John Kim, who is also in the audience. Up next, we have Zymeworks. We will be starting with a presentation by CEO, Ken Galbraith.
Ken, the stage is yours.
&
That's great. Thank you very much. Thank you for the opportunity to present today on Thursday at JPMorgan. Welcome, everyone. Thank you for attending.
Just before I get started, I just want to reflect on a year ago being on this stage, also on Thursday, right after two really important events in the company's history. One, being the first pivotal study readout for zanidatamab in second-line biliary tract cancer, which was in December right before we came to the conference, which showed some very compelling data for zanidatamab and still the potential to be the first HER2
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)